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Clinics 
Age and sex: 78 years old male patient 
Previous History : no preleukemia; no previous 
malignant disease; no inborn condition of note. 
Organomegaly : no hepatomegaly; splenomegaly; no 
enlarged lymph nodes; no central nervous system 
involvement. 
Blood 
WBC: 3.14. x 109/l; Hb: 5.7 g/dl; platelets: 86x 109/l;  
Bone marrow: increased cellularity, hyperplastic 
granulocytic series with dysgranulopoiesis, 
polymorphous and dysplastic megakaryocytes, 
numerous micromegakaryocytes, depressed erythroid 
series. Blasts: 5%, Monocytes: 17%. Note: WBC 
Differential: Neu: 23, Lymph: 31, Mono: 41, Myelo-
Metamyelocytes: 5%, granulocytic dysplasia. Absolute 
monocyte count: 1.3 x 109l 
Cytopathology classification 
Pathology: Increased cellularity, F:C ratio 5:95 mainly 
due to hyperplasia of myelocytic series with 
dysgranulopoiesis, CD34(+) cells approx. 13%, 
significant depression of erythroid series, abundant 
micromegacaryocytes. 
Precise diagnosis: Chronic myelomonocytic leukemia 
(CMML). 
Survival 
Date of diagnosis: 02-2003. 
Treatment: Supportive; blood transfusions, steroids, 
platelets transfusions. 
Complete remission: None 
Status: Dead 11-2005. 
Survival: 33 months. 
Karyotype 
Sample: Bone marrow; Culture time: Direct 
preparations (after 1 h in culture) and 24 h; Banding: 




Partial karyogram of the cytogenetically abnormal clone with 
the translocation t(2;12)(q31;p13). The arrows indicate the 
breakpoint in the abnormal chromosomes 2 and 12. 
Comments 
Among the haematological malignancies with clonal 
chromosome aberrations reported in the world 
literature, there is only one case with the same 
cytogenetic clonal evolution, since a second abnormal 
translocation t(2;12)(q31;p13), a non Hodgkin 
lymphoma published by Sato et al., 1997. The 
karyotypic findings of the present case indicates a clone 
with the translocation t(2;12)(q31;p13) and trisomy of 
chromosome 21 was identified together with the clone 
displaying the t(2;12)(q31;p13) as the sole change. 






Atlas Genet Cytogenet Oncol Haematol. 2007;11(2)  149 
References 
Sato Y, Bohlander SK, Kobayashi H, Reshmi S, Suto Y, Davis 
EM, Espinosa III R, Hoopes R, Montgomery KT, Kucherlapati 
RS, Le Beau MM, Rowley JD. Heterogeneity in the breakpoints 
in balanced rearrangements involving band 12p13 in 
hematologic malignancies identified by fluorescence in situ 
hybridization: TEL (ETV6) is involved in only one half. Blood 
1997;90:4886-4893. 
This article should be referenced as such: 
Iakovaki D, Fisfis M, Stefanoudaki K, Bardi G. Reciprocal 
translocation t(2;12)(q31;p13) in a case of CMML. Atlas Genet 
Cytogenet Oncol Haematol.2007;11(2):148-149.  
 
 
 
